Cutler Group’s Relay Therapeutics RLAY Stock Holding History

Cutler Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,500	Closed	-$3K	–	5938
2021 Q3	$3K	Buy	+1,500	New	+$50.5K	﹤0.01%	4855

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cutler Group's RLAY Position: Q3 2022 in Review

Cutler Group sold out of Relay Therapeutics (RLAY) in Q3 2022, closing a stake of 2,510 shares — an estimated $42K sold.

Cutler Group first reported a position in RLAY in Q1 2022 and held it in 2 quarters. The position peaked at $182K in Q1 2022. 161 funds tracked by Wall St. Rank hold RLAY as of Q3 2022.

Cutler Group reported no remaining Relay Therapeutics position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 2,510 Relay Therapeutics shares in Q3 2022, an estimated $42K.
Cutler Group first reported a position in Relay Therapeutics in Q1 2022 and held it in 2 quarters.
Cutler Group's Relay Therapeutics position peaked at $182K in Q1 2022.
161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.